BUFFALO, NY — The Second Niagara Lung Cancer Symposium, being held at Queen’s Landing in Niagara-on-the-Lake, Ontario, Canada, today through Sunday, September 12, represents a rare educational collaboration among national and international experts from academia, industry and government.
The Symposium, organized by Roswell Park Cancer Institute (RPCI), is a forum for governmental, pharmaceutical, scientific and medical professionals involved in various aspects of lung cancer diagnosis, prevention, treatment and research. It aims to foster transdisciplinary collaborations, all toward the goal of increasing survival rates and quality of life among lung cancer patients.
Alex A. Adjei, MD, PhD, FACP, Senior Vice President of Clinical Research and Chair of the Department of Medicine at RPCI, is program chair for the conference. Program co-chairs are Mary Reid, PhD, also from RPCI; Glenwood Goss, MD, of the Ottawa Hospital Regional Cancer Center; and Janet Dancey, MD, of the Ontario Institute for Cancer Research.
“We’re both excited about and encouraged by this opportunity to bring together such a distinguished faculty for this unparalleled opportunity for knowledge-sharing,” said Dr. Adjei, who is also the Katherine Anne Gioia Chair in Cancer Medicine at RPCI. “We’ll learn together about novel approaches to identifying biomarkers, as well as about diagnostic and treatment tools and new techniques. This conference presents the opportunity for collaboration between these world-class investigators and institutions in the fight to prevent, treat and cure lung cancer.”
RPCI staff joining Drs. Adjei and Reid as faculty members for the Symposium are Richard Cheney, MD; K. Michael Cummings, PhD, MPH; Todd Demmy, MD; Jorge Gomez, MD; Anurag Singh, MD; Graham Warren, MD, PhD and Sai Yendamuri, MD.
Also serving on the Lung Cancer Symposium faculty are researchers from nearly 30 organizations and institutions across North America: ArQule, AstraZeneca; Boston University School of Medicine; Bristol-Myers Squibb; the British Columbia Cancer Agency; City of Hope; Columbia University; Dana Farber Cancer Center; the Duke Institute for Genomic Sciences and Policy; Emory University; the Food and Drug Administration; Johns Hopkins University Medical School; the Mayo Clinic; Memorial Sloan Kettering Cancer Center; the National Cancer Institute; New York University; the Ontario Institute for Cancer Research; Ottawa Hospital Regional Cancer Center; Pfizer; Princess Margaret Hospital; the University of Calgary; the University of California, Los Angeles; the University of California, San Francisco; the University of Chicago; the University of Colorado Health Sciences Center; the University of Pennsylvania; the University of Texas Southwestern Medical Center; and Vanderbilt-Ingram Cancer Center.
Through RPCI’s Accreditation Council for Continuing Medical Education accreditation, attendees may earn up to 13.5AMA PRA Category 1 continuing medical education credits. For more information, go to http://www.cvent.com/EVENTS/Info/Summary.aspx?e=676f3d59-3698-4779-b2ec-....
RPCI gratefully acknowledges support for the Symposium from ArQule, Daiichi Sankyo, Genentech, Lilly, Merrimack, Novartis Pharmaceuticals, OSI Pharmaceuticals, Syndax Pharmaceuticals and the Stacey Scott Lung Cancer Registry, which is based at RPCI.
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email email@example.com.
Annie Deck-Miller, Senior Media Relations Manager